HXHuizhe Xu

Huizhe Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huizhe Xu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Haozhe Piao

    Department of Neurosurgery, Cancer Hospital of Dalian University of Technology,Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, People’s Republic of China

    5 shared publications
  • Haozhe Piao

    Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China.

    4 shared publications
  • Ji Shi

    Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China

    3 shared publications
  • Qiang Liu

    Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China

    3 shared publications
  • Haiyang Liang

    Department of Neurosurgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, P R China

    2 shared publications
  • Huilan Yang

    Department of Hyperbaric Oxygen, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning Province, 110003, P R China

    2 shared publications

Latest Publications

  • Open Access

    Tasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway

    by Yi Chen, Jicheng Li, Huilan Yang, Haiyang Liang, Ji Shi, Quan Li, Qiang Liu, Jia Liu, Xuanming Zhang, Huizhe Xu, et al.

    Gliomas are aggressive tumors with poor treatment outcomes. Tasimelteon, an FDA-approved melatonin receptor agonist with favorable blood-brain barrier penetration, has unexplored anti-tumor potential. This study investigated whether Tasimelteon inhibits glioma proliferation through ferroptosis induction. Cell viability, colony formation, and immunofluorescence were employed to assess the effects of Tasimelteon on glioma cells. Ferroptosis was assessed by measuring lipid peroxidation markers (MDA, 4-HNE, BODIPY 581/591 C11) and ROS levels, and mitochondrial damage was detected by TEM. Mechanisms were examined through Western blotting, qPCR, dual-luciferase reporter assays, site-directed mutagenesis and molecular docking. In vivo, LN229-Luc glioma cells were orthotopically injected into mouse brains, followed by Tasimelteon treatment. Tumor growth was monitored by bioluminescence imaging, and body weight and survival were recorded. Systemic toxicity was evaluated through H&E staining of major organs. Tasimelteon decreased glioma cell viability and colony formation in dose- and time-dependent manners. Mechanistically, Tasimelteon induced ferroptosis, characterized by elevated lipid peroxidation markers (MDA, 4-HNE) and ROS levels, along with mitochondrial damage observed by TEM. This process was accompanied by ACSL4 upregulation. Further investigation revealed that Tasimelteon bound to SP1 at Gln465 and Leu467 residues, stabilizing the protein and enhancing ACSL4 transcription, independent of MT1/MT2 receptor activation. In orthotopic glioma models, Tasimelteon suppressed tumor growth by inducing ferroptosis and prolonged survival without systemic toxicity. Tasimelteon inhibits glioma growth by inducing ferroptosis via the SP1/ACSL4 pathway, offering a novel therapeutic approach.

  • Open Access

    Advances in the Study of Intestinal Microbiota and Neuropathic Pain

    by Yuxin Jiang, Huizhe Xu, Wenshun Zhang, Shengbo Jin, Haozhe Piao, Jun Yu, Huini Yao, Jie Shi, Qian Liu, Ningxin Li, et al.

    The intestinal microbiota, present in vast numbers within the human body, plays a pivotal role, with its composition and abundance varying significantly across individuals. This gut microbiota not only contributes to normal physiological development but also impacts the initiation, progression, resolution, and prognosis of various diseases. Recent studies have increasingly illuminated the connection between intestinal microbiota and pain, with a particular focus on the relationship between gut microbiota and neuropathic pain (NP). NP, an acute and chronic pain disorder arising from sensory nervous system injury, encompasses both peripheral and central neuropathic pain. Evidence suggests that intestinal microbiota influences NP occurrence and may modulate its severity. This review synthesizes current research findings on the microbiota-NP relationship, aiming to establish a theoretical foundation for future clinical investigations.


  • Open Access

    Research progress on TMEM proteins in cancer progression and chemoresistance (Review)

    by Ji Shi, Duo Zheng, Bing Yao, Qiang Liu, Huizhe Xu, Haozhe Piao

    In cancer research, the transmembrane (TMEM) family of proteins has attracted considerable attention due to its role in tumor progression and chemoresistance. These membrane proteins are integral to cellular processes, including signal transduction, ion transport and cellular homeostasis, rendering them promising therapeutic targets. The TMEM proteins are implicated in several types of cancer, including breast, ovarian, lung and thyroid cancer, where they regulate numerous cellular processes, including proliferation, migration, invasion and survival. Notably, TMEM45A and TMEM158 contribute to resistance to platinum‑based chemotherapy by increasing the expression of proteins associated with hypoxic conditions and multidrug resistance. Additionally, epigenetic regulation, particularly promoter methylation of TMEM88, is pivotal in regulating TMEM88 expression and function in chemoresistance. The present review presents a systematic and comprehensive overview of the structural features, biological functions and regulatory mechanisms of key TMEM proteins across various types of cancer. It also highlights emerging connections between TMEM proteins and the tumor microenvironment, emphasizing their potential as promising therapeutic targets. The novel findings underscore the key role of the TMEM protein family in overcoming chemoresistance and lay a foundation for the development of targeted therapeutic strategies in cancer treatment.


  • Open Access

    Ginsenoside F2-modified liposomes delivering FTY720 enhance glioblastoma targeting and antitumor activity via ferroptosis

    by Huizhe Xu, Zhisheng Wu, Jiamei Tang, Yu Gan, Jicheng Li, Yingying Yu, Yi Chen, Rui Sui, Jia Liu, Ye Zhang, et al.


  • Open Access

    Targeting the cuproptosis‑associated gene COL22A1 in glioblastoma using EMD‑1204831 and kaempferol

    by Yi Chen, Ye Zhang, Huilan Yang, Qiang Liu, Rui Sui, Ji Shi, Haiyang Liang, Jia Liu, Huizhe Xu, Haozhe Piao

    Glioblastoma (GBM) is a disease with high morbidity and poor prognosis. The combination of traditional Chinese and Western medicine and cuproptosis are known to serve important roles in the treatment of GBM. However, targeting cuproptosis to treat GBM by combining traditional Chinese and Western medicine has not been extensively investigated. Therefore, the present study focused on the diagnosis and treatment of GBM based on cuproptosis. Through a bioinformatics approach, a cuproptosis‑related prognostic model was first constructed. Next, this prognostic model was found to be closely related to immune infiltration, DNA mutation and DNA methylation through multi‑omics analysis. The present study indicated the cell clusters in GBM tissues and the risk scores in each cluster based on single‑cell sequencing data derived from Gene Expression Omnibus. Notably, by screening the CellMiner database, EMD‑1204831 was found to exhibit a high correlation with the risk score. Next, through network pharmacology and molecular docking analysis, the risk score‑related gene collagen type XXII α1 chain (COL22A1) was identified as the target of kaempferol, which is the active component of Ginseng. Notably, kaempferol could decrease the proliferation of GBM cells by inhibiting COL22A1 expression in cell experiments. Finally, kaempferol and EMD‑1204831 had an obvious inhibitory effect on the growth of GBM and sensitized GBM to cuproptosis inducers via COL22A1 in cell and animal experiments. Overall, the present study revealed a cuproptosis‑related combined regimen for GBM.


  • Open Access

    Correction: Metabolism: an important player in glioma survival and development

    by Ning Wang, Yiru Yuan, Tianhao Hu, Huizhe Xu, Haozhe Piao

  • Open Access

    Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy

    by Sizuo Yan, Yu Gan, Huizhe Xu, Haozhe Piao

    Cancer is a major killer threatening modern human health and a leading cause of death worldwide. Due to the heterogeneity and complexity of cancer, traditional treatments have limited effectiveness. To address this problem, an increasing number of researchers and medical professionals are working to develop new ways to treat cancer. Bacteria have chemotaxis that can target and colonize tumor tissue, as well as activate anti-tumor immune responses, which makes them ideal for biomedical applications. With the rapid development of nanomedicine and synthetic biology technologies, bacteria are extensively used as carriers for drug delivery to treat tumors, which holds the promise of overcoming the limitations of conventional cancer treatment regimens. This paper summarizes examples of anti-cancer drugs delivered by bacterial carriers, and their strengths and weaknesses. Further, we emphasize the promise of bacterial carrier delivery systems in clinical translation.


  • Open Access

    Metabolism: an important player in glioma survival and development

    by Ning Wang, Yiru Yuan, Tianhao Hu, Huizhe Xu, Haozhe Piao

    Gliomas are malignant tumors originating from both neuroglial cells and neural stem cells. The involvement of neural stem cells contributes to the tumor’s heterogeneity, affecting its metabolic features, development, and response to therapy. This review provides a brief introduction to the importance of metabolism in gliomas before systematically categorizing them into specific groups based on their histological and molecular genetic markers. Metabolism plays a critical role in glioma biology, as tumor cells rely heavily on altered metabolic pathways to support their rapid growth, survival, and progression. Dysregulated metabolic processes, involving carbohydrates, lipids, and amino acids not only fuel tumor development but also contribute to therapy resistance and metastatic potential. By understanding these metabolic changes, key intervention points, such as mutations in genes like RTK, EGFR, RAS, and IDH can be identified, paving the way for novel therapeutic strategies. This review emphasizes the connection between metabolic pathways and clinical challenges, offering actionable insights for future research and therapeutic development in gliomas.